We are live on ! Find out more
FBRX icon

Forte Biosciences
FBRX

47 hedge funds and large institutions have $330M invested in Forte Biosciences in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

685% more capital invested

Capital invested by funds: $42.1M → $330M (+$288M)

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

74% more funds holding

Funds holding: 27 → 47 (+20)

1.36% more ownership

Funds ownership: 1.07% → 2.43% (+1.4%)

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

Holders
47
Holders Change
+20
Holders Change %
+74.07%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
9
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
+$77.9M
2
Franklin Resources
Franklin Resources
California
+$25.7M
3
Citadel Advisors
Citadel Advisors
Florida
+$9.03M
4
CS
Credit Suisse
Switzerland
+$4.79M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.77M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$16.2M
2
FAM
Fred Alger Management
New York
-$6.85M
3
BI
BVF Inc
California
-$5.34M
4
MA
MYDA Advisors
New York
-$159K
5
TAM
Tocqueville Asset Management
New York
-$58.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACH
1
ArrowMark Colorado Holdings
Colorado
$142M +$77.9M +117,468 New
Franklin Resources
2
Franklin Resources
California
$47M +$25.7M +38,754 New
BI
3
BVF Inc
California
$37.7M -$5.34M -8,052 -21%
FAM
4
Fred Alger Management
New York
$22.6M -$6.85M -10,333 -36%
Citadel Advisors
5
Citadel Advisors
Florida
$16.5M +$9.03M +13,625 New
O
6
OrbiMed
New York
$16.5M -$16.2M -24,394 -64%
CS
7
Credit Suisse
Switzerland
$8.76M +$4.79M +7,224 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$8.01M +$2.77M +4,173 +172%
BlackRock
9
BlackRock
New York
$5.1M +$1.48M +2,229 +113%
ACM
10
Asymmetry Capital Management
California
$3.87M +$2.12M +3,193 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$3.71M +$1.51M +2,281 +293%
Qube Research & Technologies (QRT)
12
Qube Research & Technologies (QRT)
United Kingdom
$2.12M +$1.16M +1,746 New
MA
13
MYDA Advisors
New York
$1.65M -$159K -240 -15%
EGI
14
EAM Global Investors
California
$1.5M +$823K +1,241 New
DC
15
Davenport & Co
Virginia
$1.3M +$711K +1,072 New
EI
16
EAM Investors
California
$1.05M +$576K +869 New
Invesco
17
Invesco
Georgia
$999K +$546K +824 New
Northern Trust
18
Northern Trust
Illinois
$946K +$410K +619 +384%
California Public Employees Retirement System
19
California Public Employees Retirement System
California
$893K +$488K +736 New
SC
20
Sepio Capital
Utah
$893K +$488K +736 New
CIBC Private Wealth Group
21
CIBC Private Wealth Group
Georgia
$857K – – –
Jane Street
22
Jane Street
New York
$639K +$78.9K +119 +29%
PHP
23
Parkman Healthcare Partners
Connecticut
$606K +$331K +500 New
Two Sigma Investments
24
Two Sigma Investments
New York
$606K +$331K +500 New
Renaissance Technologies
25
Renaissance Technologies
New York
$598K +$327K +493 New
1
2 3

FBRX Hedge Fund Activity: Q3 2020 in Review

47 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2020, worth a combined $330M — up 685% from $42.1M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new FBRX positions and 5 closed out — a net gain of 20 holders — while 9 added to existing stakes and 9 trimmed.

The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $77.9M. The largest seller was OrbiMed, cutting an estimated $16.2M.

  • 47 institutional investors held Forte Biosciences (FBRX) as of Q3 2020, up from 27 in Q2 2020.
  • Funds reported $330M of Forte Biosciences stock for Q3 2020, up 685% quarter-over-quarter.
  • 25 funds opened new Forte Biosciences positions in Q3 2020 and 5 closed out, a net change of +20 holders.
  • The largest Forte Biosciences buyer in Q3 2020 was ArrowMark Colorado Holdings, an estimated $77.9M added.
  • The largest Forte Biosciences seller in Q3 2020 was OrbiMed, an estimated $16.2M sold.

Based on aggregated 13F filings for Q3 2020.